Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase III Pipeline Programs

Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Programs 5,427
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 5,427 phase iii pharmaceutical pipeline programs from ClinicalTrials.gov. Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Top sponsors

Pipeline programs

Page 5 of 114

  1. 230LE303

    Biogen

    systemic lupus erythematosus

    phase 3 small molecule active

    1 trial

  2. 230LE304

    Biogen

    systemic lupus erythematosus

    phase 3 small molecule active

    1 trial

  3. 230LE306

    Biogen

    Systemic lupus erythematosus

    phase 3 small molecule active

    1 trial

  4. 233AS303

    Biogen

    Amyotrophic Lateral Sclerosis (ALS) associated with SOD1 gene mutation

    phase 3 small molecule active

    1 trial

  5. 241502

    Takeda

    Hemophilia A

    phase 3 mab terminated

    1 trial

  6. 25 mg Ontamalimab

    Takeda

    Crohn's Disease

    phase 3 small molecule completed

    1 trial

  7. 25% AgNO3 solution followed by 5% NaF

    The University of Hong Kong

    Early Childhood Caries

    phase 3 small molecule completed

    1 trial

  8. 2693-CL-1303

    Astellas Pharma GmbH

    Moderate to Severe Vasomotor Symptoms (VMS)

    phase 3 small molecule active

    1 trial

  9. 299AR301

    Biogen

    Kidney Transplant Recipients with Late Antibody-Mediated Rejection

    phase 3 small molecule active

    1 trial

  10. 299IG301

    Biogen

    IgA nephropathy

    phase 3 small molecule active

    1 trial

  11. 2mg Baricitinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Ichemic Stroke

    phase 3 small molecule active

    1 trial

  12. 3-N-butylphthalide

    Second Affiliated Hospital, School of Medicine, Zhejiang University

    Multiple System Atrophy

    phase 3 small molecule active

    1 trial

  13. 3-N-butylphthalide

    The First People's Hospital of Lianyungang

    Multiple System Atrophy

    phase 3 small molecule active

    1 trial

  14. 3-dimensional conformal radiation therapy

    United Therapeutics Europe Ltd

    Head and Neck Cancer

    phase 3 other active

    1 trial

  15. 3-second SDF application

    The University of Hong Kong

    Early Childhood Caries

    phase 3 other completed

    1 trial

  16. 333-301

    BioMarin Pharmaceutical Australia Pty Ltd

    Achondroplasia

    phase 3 small molecule active

    1 trial

  17. 36-71 months old children-experimental EV71 vaccine.

    Sinovac Research and Development Co.,

    Hand, Foot and Mouth Disease

    phase 3 mab completed

    1 trial

  18. 4-aminopyridine

    United Therapeutics Europe Ltd

    Spinal Muscular Atrophy

    phase 3 small molecule completed

    1 trial

  19. 40 mg/day vormatrogine for 12 weeks

    Chongqing Precision Biotech Co., Ltd

    Focal Epilepsy

    phase 3 small molecule active

    1 trial

  20. 400U /0.5ml EV71 vaccine

    Sinovac Research and Development Co.,

    Hand, Foot and Mouth Disease

    phase 3 mab completed

    1 trial

  21. 4010-03-001

    TESARO Bio Netherlands B.V.

    Recurrent or primary advanced (Stage III or IV) endometrial cancer

    phase 3 small molecule active

    1 trial

  22. 4045-301

    Sarepta Therapeutics

    Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping.

    phase 3 small molecule active

    1 trial

  23. 410701BS

    Lacuna Pharma Pty Ltd

    Plaque psoriasis

    phase 3 small molecule active

    1 trial

  24. 42-1703

    Aquestive Therapeutics

    Epilepsy

    phase 3 small molecule completed

    1 trial

  25. 4202-HEM-301

    NovoThirteen

    sickle cell disease (SCD)

    phase 3 small molecule active

    1 trial

  26. 42756493BLC3001

    Janssen-Cilag International N.V.

    Advanced Urothelial Cancer

    phase 3 small molecule active

    1 trial

  27. 42756493BLC3004

    Janssen-Cilag International N.V.

    FGFR+ Intermediate-risk Non-muscle Invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

  28. 42756493BLC3005

    Janssen-Cilag International N.V.

    High-risk Non-muscle-invasive Bladder Cancer with Susceptible FGFR Alterations

    phase 3 small molecule active

    1 trial

  29. 4D-150 IVT (3E10 vg/eye)

    4D Molecular Therapeutics

    Macular Neovascularization Secondary to Age-Related Macular Degeneration

    phase 3 mab active

    1 trial

  30. 4D-150 IVT (3E10 vg/eye)

    4D Molecular Therapeutics

    Neovascular Age-Related Macular Degeneration (nAMD)

    phase 3 mab active

    1 trial

  31. 4D-150-C004

    4D Molecular Therapeutics

    Macular neovascularization secondary to age-related macular degeneration (nAMD)

    phase 3 small molecule active

    1 trial

  32. 5 mg Serlopitant Tablets

    VYNE Therapeutics

    Pruritus

    phase 3 small molecule terminated

    3 trials

  33. 5 mg Tadalafil

    Eli Lilly and Company

    Benign Prostate Hyperplasia

    phase 3 small molecule completed

    1 trial

  34. 5 mg prednisone

    Ultragenyx UK Limited

    Granulomatosis With Polyangiitis

    phase 3 small molecule active

    2 trials

  35. 5% Lidocaine patch

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Herpes Zoster Pain

    phase 3 small molecule completed

    1 trial

  36. 5% cysteamine cream

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Melasma

    phase 3 other completed

    1 trial

  37. 5% minoxidil foam

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Androgenetic Alopecia

    phase 3 small molecule active

    1 trial

  38. 5-Fluorouracil

    Hoffmann-La Roche

    Breast Cancer

    phase 3 small molecule completed

    1 trial

  39. 5-Fluoruracil

    Hoffmann-La Roche

    Gastric Cancer

    phase 3 small molecule completed

    1 trial

  40. 5-Fu/epirubicin/CTX following Docetaxel

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Cancer

    phase 3 small molecule active

    1 trial

  41. 54135419SUI3003

    Janssen-Cilag International N.V.

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  42. 54767414AMY3001

    Janssen-Cilag International N.V.

    AL Amyloidosis (Newly Diagnosed Systemic AL Amyloidosis)

    phase 3 small molecule active

    1 trial

  43. 54767414MMY3019

    Janssen-Cilag International N.V.

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  44. 56021927PCR3001

    Janssen-Cilag International N.V.

    Metastatic castration-resistant prostate cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  45. 56021927PCR3002

    Janssen-Cilag International N.V.

    Metastatic Hormone-sensitive Prostate Cancer

    phase 3 small molecule active

    1 trial

  46. 56021927PCR3015

    Janssen-Cilag International N.V.

    High risk recurrent prostate cancer previously treated with radical prostatectomy

    phase 3 small molecule active

    1 trial

  47. 5mg Serlopitant Tablets

    VYNE Therapeutics

    Pruritus

    phase 3 small molecule completed

    2 trials

  48. 6% Hydroxy-ethyl starch (130/0.4)

    The George Institute

    Intensive Care

    phase 3 small molecule completed

    1 trial

Frequently asked questions

How many Phase III pipeline programs are in the directory?

5,427 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.